Medpace Holdings Inc vs TeraWulf Inc — how do they compare? Medpace Holdings Inc trades at $615.17 (market cap $16.82B), while TeraWulf Inc trades at $13.65 (market cap $6.81B). The key difference: Medpace Holdings Inc is far larger — about 2.5× TeraWulf Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and TeraWulf Inc for 17 Days on average.
| MEDP | WULF | |
|---|---|---|
Market Cap | $16.82B | $6.81B |
Volume | 223,093 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $630.19 | $28.98 |
52-Week Low | $393.42 | $10.99 |
Typical Hold Time | 14 Days | 17 Days |
Enterprise Value | $16.44B | $9.43B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
TeraWulf (WULF) trades at $13.73, down 4.65% today, amid bearish technical signals despite unanimous analyst optimism. The stock shows severe fundamental strain with negative profit margins (-1,179.94% net income margin) and consecutive earnings misses, though revenue remains stable near $168M. Recent news highlights the company's pivot to AI data center operations, with UBS initiating bullish coverage citing long-term power access advantages.
While analyst consensus points to significant upside (average target $34.92), the stock faces substantial execution risks in its AI transition amid persistent cash burn. Investors must weigh Wall Street's optimistic price targets against the company's current negative profitability and high valuation multiples in a competitive infrastructure sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →